Caregiver's Home Companion Caring for someone who has trouble hearing the phone?
 HOME PAGE  SEARCH Go

Posted: February 05, 2008

Estrogen-like Compound May Reduce Risk for Alzheimer's in Mice: Report

An artificial compound similar to the female hormone estrogen may hold a key in unlocking the mystery of how best to slow or treat Alzheimer’s disease after researchers turned up positive results in a study involving mice.
 
New research accepted for publication in the journal Endocrinology reveals that mice with induced Alzheimer’s-like symptoms had improved cognitive function when given the synthetic estrogen-like hormone propylpyrazole triol (PPT). In essence, the mice received what amounted to a synthetic form of hormone therapy.
 
“This synthetic hormone improved behavior much the way that estrogen does,” said study leader Dr. Christian Pike, associate professor at the University of Southern California’s School of Gerontology. But unlike estrogen, which enlarges the uterus and is a known risk factor for endometrial and breast cancer, PPT caused no obvious changes to the animals’ reproductive tract.
 
“This may be a promising strategy to maximize hormone therapy benefits and minimize its risk,” said Pike.
 
Estrogen-based hormone therapy has long been studied as a therapeutic option for postmenopausal women to reduce the risk of several age-related disorders, including osteoporosis and Alzheimer’s disease. Some studies have suggested that estrogen may lower the risk of Alzheimer’s. This natural hormone, however, has also been associated with a number of adverse health effects.
 
A potential alternative approach to estrogen-based hormone therapy is a synthetic form of the hormone known as selective estrogen receptor modulators (SERMs). SERMs can have the same effect as estrogen, but specifically target certain tissues and certain parts of the body. Two recently developed SERMs -- PPT and diarylpropionitrile (DPN) -- have been shown to protect cultured neurons from damage.
 
For their study, the researchers examined the effects of estrogen, PPT, and DPN on female mice. The data confirmed previous studies showing that estrogen significantly reduced the buildup in the brain of the protein beta amyloid, which has been implicated in the development of Alzheimer’s disease. Estrogen also reduced cognitive decline in the mice.
 
The researchers also observed that PPT was effective in lowering beta amyloid accumulation in most brain regions and also lessened working memory deficits. PPT also appeared to have no adverse impact on the animals’ reproductive tracts.
 
However, DPN did not demonstrate the same protective effects, according to the study team.
 
“These findings suggest it may be possible to design an optimal compound that offers the best protection with the least risk,” said Pike. “This study also should encourage further animal and human research on the potential benefits of SERMs.”
 
The study was funded by the National Institute on Aging.

Email or share this story Bookmark and Share

Search CaregiversHome
Find with keyword(s):

Enter a keyword or phrase to search CaregiversHome's archives for related news topics, the latest news stories, timely times, and reference articles.

© 2008 Pederson Publishing, Inc. All Rights Reserved.
Commercial use, redistribution or other forms of reuse of this information is strictly prohibited without the prior written permission of Pederson Publishing.

_____

View The Caregiver's Hotline in which this article first appeared

Back to Top

Privacy Statement Contact Us Site Map Products & Services Our Partners Advertise
© Copyright 2003-2020. Pederson Publishing, Inc. All rights reserved.